Fauna Bio, a Berkeley, Calif.-based biotechnology company leveraging the science of hibernation to improve healthcare for humans, raised a total of $4.1m in seed funding.
The round was led by True Ventures with participation from Longevity Fund and Pacific 8 Ventures, Boom Capital and Beagle Ventures.
The company will use the new funds to expand its discovery platform to help find new therapeutic targets for human diseases.
Co-founded by Dr. Ashley Zehnder, CEO, Dr. Linda Goodman and Dr. Katharine Grabek, Fauna Bio provides a drug-discovery platform whose first version focuses on hibernating mammals for adaptation-inspired therapeutics. Hibernating animals have natural adaptations, providing insights into critical human health problems such as Alzheimer’s disease, heart disease, osteoporosis, obesity/diabetes and traumatic injury.